Abstract
Post-training administration (ICV) of gamma-L-glutamyl-L-aspartate (gamma-LGLA) or D-2-amino-5-phosphonovalerate (D-AP5), a competitive NMDA antagonist, decreased retention of the temporal component but not the spatial discrimination component of a Y-maze active avoidance task. Inverted U-shaped dose-response curves were obtained for the ability of gamma-LGLA and D-AP5 to decrease retention, with maximum effects occurring at doses of 2-20 nmol/mouse for gamma-LGLA and 0.02 nmol/mouse for D-AP5. gamma-LGLA and D-AP5 impaired the traction reflex only at doses (80 and 2 nmol/mouse, respectively) higher than those producing retention deficits. Convulsions induced by ICV administration of 1 nmol NMDA were antagonized by gamma-LGLA and D-AP5 with ED50 values of 46 (32-66) and 0.2 (0.16-0.25) nmol/mouse, respectively. The dose-effect curve of NMDA for producing convulsions was shifted to the right in a parallel manner and to the same extent by 80 nmol gamma-LGLA and by 0.3 nmol D-AP5. Taken together, these results are consistent with previous studies suggesting that the behavioral effects of gamma-LGLA might be related to its NMDA receptor antagonist properties. The selectivity of the memory deficits induced by gamma-LGLA and D-AP5 is in agreement with recent reports suggesting a role for NMDA receptors in the mechanisms underlying posttraining organization of memory traces.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
